Innovation Pharmaceuticals Inc (IPIX)

[petemantx]

My point is that people are talking about P for psoriasis and that market is about $12B or so. The markets for other autoimmune drugs dwarf that.

Brilacidin - OM is the runt of the litter as far as market goes. The dermatology arm alone is in the $30-40B/yr range, the IBD market is the third biggest behind cancer and heart disease, and ABSSSI is not even mentioned.

So overall, talking about IPIX as a few $B market when more further developed is outlandish IMO.

Right now, I say take a nice initial payment in the double digit MM range, triple digit platform range, and retain a very healthy royalty schedule so that both the BP and IPIX soar in value if drugs perform well in a number of currently untested areas and if they don't do that well the BP is not out anything based on what we already know as to the value in psoriasis, ABASSI, IBD, and OM today.